Cite
MLA Citation
Dean Andrew et al.. “P-287Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): a randomized, open-label phase 2 study.” Annals of oncology, vol. 27, n.d., p. ii84. http://access.bl.uk/ark:/81055/vdc_100097077855.0x000019